| FINANCIAL DATA |
 |
| Group information |
Chairman's Message
 |
 |
Thierry
BOIRON
Director and Chief Executive Officer |
Christian
BOIRON
Chairman of the Board of Directors |
Our medicines enjoy growing credibility every day
The troubled period we're experiencing is one that is favourable for new approaches in all areas, including in medicine, in pharmaceuticals, in health economics.
More than ever our family structure enables us to flexibly adapt to economic challenges, with the motivation and all-out efforts of all Boiron’s employees being the key to our performance. Regardless of the field, our homeopathy offers significant advantages that we daily strive to bring more and more to the fore.
Our medicines enjoy growing credibility, both as a result of their commercial success and through scientific proof of their clinical effectiveness.
Oscillococcinum® is already the leader in France in the field of influenza, Stodal® syrup has become the number one cough syrup in Poland and Euphralia® is the number two eye drop for eye irritation in Italy.
Other high-potential OTC specialties follow including Homéoplasmine®, Cicaderma®, Cocculine®, and Sédatif PC®...
We currently account for less than 0.1% of the global medicine market... just imagine our growth potential!
Thierry
BOIRON
Director and Chief Executive Officer
|
|
Christian
BOIRON
Chairman of the Board of Directors |
|
